Clinical Updates & Insights

MSK researchers have identified genomic changes in recurrent gastric tumors that could improve personalized care and post-operative monitoring of this deadly type of cancer. In the study, researchers used large-scale genetic sequencing data to identify patients at risk of recurrence of primary gastric cancer, and to predict the pattern of metastasis after surgery.

In this Q&A series, we speak with former MSK trainees as they reflect on their career paths, share insights from their current work, and discuss how their experiences at MSK continue to inform the way they practice, lead and innovate. For this edition, we spoke with Justin Jee, MD, PhD, a graduate of MSK's Medical Oncology Fellowship. Dr. Jee is a thoracic medical oncologist and physician-scientist at MSK, where he cares for patients with lung cancer.

This Q&A with lymphoma specialist Mark Roschewski, MD, explores how targeted therapies and highly sensitive blood-based ctDNA testing could transform the future of lymphoma care by enabling more precise, personalized treatment decisions. He also discusses MSK-led research using ctDNA to detect disease earlier, assess treatment response, and better predict which patients are likely to remain disease-free after treatment.

Researchers at MSK found that combining belzutifan with lenvatinib significantly delayed disease progression in patients with advanced clear cell renal cell carcinoma whose cancer had progressed after immunotherapy. Results from the phase 3 LITESPARK-011 trial showed the combination extended progression-free survival compared with standard treatment with cabozantinib.

MSK’s inpatient radiation oncology consult service (IROC) may improve end of life care and quality of life for patients with metastatic cancer, according to new research published in JAMA Network Open on June 1, 2026.

For years, patients with triple negative breast cancer have had limited treatment options beyond chemotherapy. Now, findings from the landmark TROPION-Breast02 trial \ led by MSK researchers have established a new standard of care for this hard-to-treat breast cancer subtype.

MSK experts presented breakthrough findings in several areas of cancer research at the 2026 ASCO Annual Meeting. Highlights include advances in the treatment of liposarcoma, hepatocellular carcinoma, non-small cell lung cancer, prostate cancer, and multiple myeloma.

The heterogeneous nature of peripheral T-cell lymphoma has long complicated treatment development, with therapies that show activity in one subtype often proving less effective in others. Now researchers at MSK are using a growing molecular understanding of these diseases to guide the development of more targeted and rational treatment strategies.

Endometrial cancer is the most common gynecologic malignancy, yet incidence and mortality continue to rise. Advanced and recurrent disease carries a poor prognosis, and there are limited effective treatment options. Gynecologic medical oncologist at Memorial Sloan Kettering Cancer Center, Maria M. Rubinstein, MD, and colleagues conducted a Phase 2 study evaluating the efficacy and safety of PARP inhibitor olaparib plus immunotherapy pembrolizumab in patients with persistent or recurrent CN-H/p53-abnormal endometrial cancer, and concluded that this should be considered a potential treatment option for this population.

In this Q&A series, we speak with former MSK trainees as they reflect on their career paths, share insights from their current work, and discuss how their experiences at MSK continue to inform the way they practice, lead and innovate. These conversations bring to life the lasting impact of training at MSK, and the evolving ways our alumni shape clinical practice, and advance care for patients.